加味升降散对饮停胸胁型结核性胸膜炎患者胸腔积液ADA,外周血Treg细胞及DC细胞亚群的影响

发布时间：2018-03-13 06:49

本文选题：加味升降散　切入点：饮停胸胁型　出处：《中国实验方剂学杂志》2017年12期 　论文类型：期刊论文

【摘要】：目的:探讨饮停胸胁型结核性胸膜炎(TBP)患者应用加味升降散对其胸腔积液腺苷脱氨酶(ADA)及外周血调节性T细胞(Treg)与树突状细胞(DC)细胞亚群的影响。方法:选取河北大学附属医院2014年1月—2015年9月收治的134例TBP患者,按照随机数字表法均分为两组。对照组予以胸腔穿刺抽液+抗结核药物的常规治疗;观察组在此基础上,给予加味升降散治疗。记录比较两组连续治疗2个月时临床疗效,胸腔积液ADA水平,外周血Treg与DC细胞亚群占外周血单个核细胞(PBMC)的百分比。结果:连续治疗2个月后,观察组总有效率(95.52%)高于对照组(83.58%)(P0.05)。两组治疗2个月时胸腔积液ADA水平均显著低于治疗前(P0.01);与对照组同期比较,观察组治疗2个月时胸腔积液ADA水平显著降低(P0.01)。与治疗前比较,两组患者治疗2个月时CD25~+/PBMC,CD25~+/CD4~+及CD25~+FoxP3~+/CD25~+均显著降低(P0.01);且观察组治疗2个月时外周血Treg细胞亚群改善程度较对照组同期降低显著(P0.01)。两组治疗2个月时DC1/PBMC,DC2/PBMC及DC1/DC2均明显高于治疗前(P0.05);且与对照组同期比较,观察组治疗2个月时外周血DC细胞亚群改善幅度更为明显(P0.05)。结论:TBP患者在常规西医治疗基础上应用加味升降散更能有效改善其临床症状,降低胸腔积液ADA水平,调节机体细胞免疫,疗效切实,为临床防治TBP提供了新思路。
[Abstract]:Objective: to investigate the effects of Jiawei Shengsheng Powder on Ada in pleural effusion, T cell subsets and dendritic cell subsets in patients with tuberculous pleurisy due to pleural arrest. Methods: to study the effect of Jiawei Shengshang Powder on the subsets of adenosine deaminase (ADAA) and peripheral blood regulatory T cells (T cells) and dendritic cells (DC) in patients with tuberculous pleurisy. From January 2014 to September 2015, 134 patients with TBP were treated in the affiliated Hospital of North University. According to the method of random number table, the control group was given routine treatment of antituberculous drugs through thoracic puncture, and the observation group was treated with Jiawei Shengshang powder on this basis. The clinical effects of the two groups were recorded and compared after 2 months of continuous treatment. The level of ADA in pleural effusion, the percentage of peripheral blood Treg and DC cell subsets in peripheral blood mononuclear cells (PBMC). Results: after 2 months of continuous treatment, The total effective rate of the observation group (95.52) was higher than that of the control group (83.58). The ADA level of pleural effusion in the two groups was significantly lower than that in the control group at 2 months after treatment, and the level of ADA in the observation group was significantly lower than that in the control group at the same time. After 2 months of treatment, CD25- / -PBMC, CD25- / -CD4and CD25- FoxP3- / CD25- decreased significantly, and the improvement of peripheral blood Treg cell subsets in the observation group was significantly lower than that in the control group at the 2nd month compared with the control group. After 2 months of treatment, DC1 / PBMCDC2P / PBMC and DC1/DC2 in the two groups were significantly lower than those in the control group. It was higher than that before treatment (P 0.05) and compared with the control group in the same period. In the observation group, the subsets of DC cells in peripheral blood were significantly improved at 2 months after treatment. Conclusion the treatment of Jiawei Shengsheng Powder on the basis of routine western medicine treatment can effectively improve the clinical symptoms and reduce the level of ADA in pleural effusion. Regulation of cellular immunity, effective, for clinical prevention and treatment of TBP provides a new idea.
【作者单位】：河北大学附属医院北院;
【基金】：保定市科技局立项课题项目(10ZF059)
【分类号】：R259

【相似文献】